SparingVision announces the scientific and investor conferences that its management team will be participating in the second half of 2021.

.

Paris, September 1, 2021 – SparingVision (or the “Company”), a genomic medicine company developing vision saving treatments for ocular diseases, announces the scientific and investor conferences that its management team will be participating in the second half of 2021.

 

Investor and Industry Conferences:

HealthTech Innovations Days, 4-5 October

  • How to have the right talents in our European Companies Panel Discussion, Stéphane Boissel, President & CEO (October 5, 3:05-3:45pm CET)

Chardan’s 5th annual Genetic Medicines Conference, 4-5 October

  • Company presentation, Stéphane Boissel, President & CEO and Dr. Daniel Chung, Chief Medical Officer (October 4, 11:00am EST)

Sachs 21st Annual Biotech in Europe Forum, 7-8 October

  • Pharma-Biotech Industry Review Panel Discussion, Stéphane Boissel, President & CEO (October 7, 09:30am CET)

Cell & Gene Meeting on the MESA,  12 – 14 October

Company presentation and business update, Stéphane Boissel, President & CEO and Dr. Daniel Chung, Chief Medical Officer

BMO & Solebury Trout’s Fall Life Sciences Private Company Showcase, 14 October

  • Company presentation and business update, Stéphane Boissel, President & CEO

Jefferies, Gene Therapy/Editing Summit, 27-28 October

  • Company presentation and business update, Stéphane Boissel, President & CEO

 

Scientific Conferences:

International Society of Genetic Eye Diseases and Retinoblastoma, 2-4 September

  • Symposium on Gene Therapy (nuclear genes), Dr. Daniel Chung, Chief Medical Officer, moderator (September 2, 11:30-12:00 CET)
  • Select Strategies for Gene Agnostic Approaches to Cone Photoreceptor Function Preservation, Dr. Daniel Chung, Chief Medical Officer, (Abstract: OcGen104, September 2, 12:02-12:12 CET)

Gene Therapy for Ophthalmic Disorders, 21-23 September

  • Defining Novel Endpoints for IRDs, Dr. Daniel Chung, Chief Medical Officer, (September 22, 14:40-15:00 EST) followed by Q&A and Panel Discussion (September 22, 15:00-15:30 EST)
  • Gene Agnostic Approaches Targeting Later Stage Diseases for Photoreceptor Function, Dr. Daniel Chung, Chief Medical Officer, (September 23, 13:00-13:20 EST), followed by Q&A and Panel Discussion (September 23, 14:00-14:30 EST)

19th International Symposium of Retinal Degeneration “RD 2021”, 27 September – 7 October

Retina Society’s 54th Annual Scientific Meeting, 27 September – 2 October

American Academy of Ophthalmology, AAO 2021, 13-15 November 2021

American College of Toxicology 42nd Annual Meeting, ACT 2021, 14-17 November 2021

Gene Therapy for Rare Disorders Europe, 2-4 November

  • Transitioning Effectively from Clinical to Commercial Manufacturing, Panel Discussion, Dr. Rajiv Gangurde, Chief Technology Officer (November 3, 3pm GMT)
  • Analytics & Characterization of Gene Therapy Products, Dr. Rajiv Gangurde, Chief Technology Officer (November 4, 11:30am GMT)

Ophthalmic Drugs Conference, 22-23 November

  • Ocular Gene Therapy, basic tenets, current and future of ocular gene therapies, Dr. Daniel Chung, Chief Medical Officer, (November 23, 9:10 -9:50am GMT)
  • Panel Discussion: Genetic Therapy for Inherited Ocular Diseases, Daniel Chung, Chief Medical Officer, (November 22, 11:40-12:20pm, GMT)

**ENDS**

 
 
NOTES TO EDITORS:
 
About SparingVision:

SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.

 
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.